A Bayesian Dose-Individualization Method for Warfarin

BackgroundWarfarin is a difficult drug to dose accurately and safely due to large inter-individual variability in dose requirements. Current dosing strategies appear to be sub-optimal, with reports indicating that patients achieve international normalized ratios (INRs) within the therapeutic range only 40–65 % of the time. The consequences of poor INR control are potentially severe with INRs below 2 carrying an increased risk of clotting while INRs >4 increase the risk of major bleeding events. Bayesian forecasting methods have the potential to improve INR control.AimsThe aims of this study were to (1) prospectively assess the predictive performance of a Bayesian dosing method for warfarin implemented in TCIWorks; and (2) determine the expected time in the therapeutic range (TTR) of INRs predicted using TCIWorks.MethodsPatients who were initiating warfarin therapy were prospectively recruited from Dunedin Hospital, Dunedin, New Zealand. Warfarin doses were entered into TCIWorks from the first day of therapy until a stable steady-state INR (INRss) was achieved. The predicted INRss values were determined using the first zero to six serially collected INR observations. Observed and predicted INRss values were compared using measures of bias (mean prediction error [MPE]) and imprecision (root mean square error [RMSE]). The TTR was determined by calculating the percentage of predicted INRss values between 2 and 3 when zero to six serially collected INR observations were available.ResultsA total of 55 patients were recruited between March and November 2011. When no observed INR values were available the resulting INRss predictions were positively biased (MPE 0.52 [95 % CI 0.30, 0.73]); however, this disappeared once observed INR values were entered into TCIWorks. The precision of the predicted INRss values improved dramatically once three or more observed INR values were available (RMSE <0.53) compared with no INRs (RMSE 0.96). These results suggest that TCIWorks will be effective at maintaining the INR within the therapeutic INR range (2–3) 65 % of the time when three INR measurements are available and 80 % of the time when six INR measurements are available.ConclusionThe TCIWorks warfarin dosing method produced accurate and precise INRss predictions. We predict that the method will provide an INR value within the therapeutic range 65–80 % of the time once three or more INR observations are available, making this a useful tool for clinicians and warfarin clinics. Further research to assess the impact of this method on long-term INR control is warranted.

[1]  M. Meyer,et al.  Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do? , 2012, Journal of clinical pharmacy and therapeutics.

[2]  N. Holford,et al.  Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. , 2004, British journal of clinical pharmacology.

[3]  W. Ageno,et al.  A Computer Generated Induction System for Hospitalized Patients Starting on Oral Anticoagulant Therapy , 2000, Thrombosis and Haemostasis.

[4]  M. Daschbach,et al.  Initiation of warfarin therapy: comparison of physician dosing with computer-assisted dosing. , 1987, Journal of general internal medicine.

[5]  B. Horne,et al.  Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.

[6]  J. Deely,et al.  A sequential Bayesian algorithm for dose individualisation of carboplatin , 1997, Cancer Chemotherapy and Pharmacology.

[7]  R. Pendleton,et al.  Gene-Based Warfarin Dosing Compared With Standard of Care Practices in an Orthopedic Surgery Population: A Prospective, Parallel Cohort Study , 2010, Therapeutic drug monitoring.

[8]  A. Forster,et al.  Effect of Study Setting on Anticoagulation Control * , 2006 .

[9]  R. Kravitz,et al.  From Insight to Implementation: Lessons from a Multi-site Trial of a PDA-based Warfarin Dose Calculator , 2005 .

[10]  T. Theofanous,et al.  Multiple-dose kinetics of oral anticoagulants: methods of analysis and optimized dosing. , 1973, Journal of pharmaceutical sciences.

[11]  A. Forster,et al.  Frequency of adverse events in patients with poor anticoagulation: a meta-analysis , 2007, Canadian Medical Association Journal.

[12]  A. Forster,et al.  Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis , 2008, Canadian Medical Association Journal.

[13]  Y. Caraco,et al.  CYP2C9 Genotype‐guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study , 2008, Clinical pharmacology and therapeutics.

[14]  Susan Regan,et al.  Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation , 2007, Circulation.

[15]  David C. Anderson,et al.  Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. , 1996, Archives of internal medicine.

[16]  C. Staatz,et al.  Maximum A Posteriori Bayesian Estimation of Mycophenolic Acid Area Under the Concentration-Time Curve: Is This Clinically Useful for Dosage Prediction Yet? , 2011, Clinical pharmacokinetics.

[17]  B. Eliasson,et al.  Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. , 2012, Thrombosis research.

[18]  Stephen B. Duffull,et al.  Development of a Bayesian Forecasting Method for Warfarin Dose Individualisation , 2011, Pharmaceutical Research.

[19]  M. Bhavnani,et al.  A WARFARIN INDUCTION REGIMEN FOR OUT‐PATIENT ANTICOAGULATION IN PATIENTS WITH ATRIAL FIBRILLATION , 1998, British journal of haematology.

[20]  H. Echizen,et al.  CYP2C9 and Oral Anticoagulation Therapy with Acenocoumarol and Warfarin: Similarities yet Differences , 2004, Clinical pharmacology and therapeutics.

[21]  Lewis B. Sheiner,et al.  Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[22]  C. Kirkpatrick,et al.  Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens. , 2003, British journal of clinical pharmacology.

[23]  P. J. Ryan,et al.  Computer control of anticoagulant dose for therapeutic management. , 1989, BMJ.

[24]  L B Sheiner,et al.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. , 1982, Journal of pharmaceutical sciences.

[25]  Anticoagulants in the Secondary Prevention of Events in Coronary Group Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction , 1994, The Lancet.

[26]  D. Mungall,et al.  Outpatient management of warfarin therapy: comparison of computer-predicted dosage adjustment to skilled professional care. , 1991, Therapeutic drug monitoring.

[27]  Implementation of a Data-based Medical Event Reporting System in the U.S. Department of Defense -- Advances in Patient Safety: From Research to Implementation (Volume 3: Implementation Issues) , 2005 .

[28]  P J Huber,et al.  A Bayesian feedback method of aminoglycoside dosing , 1985, Clinical pharmacology and therapeutics.

[29]  D. Pennell,et al.  Cardiovascular magnetic resonance of left ventricular pseudoaneurysm , 2005, Heart.

[30]  A. Forster,et al.  Effect of study setting on anticoagulation control: a systematic review and metaregression. , 2006, Chest.

[31]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.

[32]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[33]  A. Boddy,et al.  Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients. , 1995, European journal of cancer.

[34]  G. Raskob,et al.  Predicting the Daily Prothrombin Time Response to Warfarin , 1990, Therapeutic drug monitoring.

[35]  M G Amato,et al.  Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. , 1998, Archives of internal medicine.

[36]  J. Schellens,et al.  Bayesian Pharmacokinetically Guided Dosing of Paclitaxel in Patients with Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[37]  N H Holford,et al.  The Target Concentration Approach to Clinical Drug Development , 1995, Clinical pharmacokinetics.

[38]  N. Holford Clinical Pharmacokinetics and Pharmacodynamics of Warfarin , 1986, Clinical pharmacokinetics.

[39]  D. Mungall,et al.  The use of a Bayesian forecasting model in the management of warfarin therapy after total hip arthroplasty. , 1999, The Journal of arthroplasty.

[40]  John Anderson Computer assisted management of warfarin treatment , 1984 .

[41]  L. Aarons,et al.  A Bayesian Method Based on Clotting Factor Activity for the Prediction of Maintenance Warfarin Dosage Regimens , 2003, Therapeutic Drug Monitoring.

[42]  Peter Wood,et al.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.

[43]  J. Jespersen,et al.  Multicentre randomised study of computerised anticoagulant dosage , 1998, The Lancet.

[44]  D. P. Bentley,et al.  Flexible induction dose regimen for warfarin and prediction of maintenance dose. , 1984, British medical journal.

[45]  N H Holford,et al.  Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. , 1986, Clinical pharmacokinetics.

[46]  P. Deloukas,et al.  A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age , 2010, Clinical pharmacology and therapeutics.

[47]  P. Lavori,et al.  Effect of home testing of international normalized ratio on clinical events. , 2010, The New England journal of medicine.

[48]  D. Mungall,et al.  Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation. , 1985, Therapeutic drug monitoring.

[49]  K. Hampton,et al.  A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. , 2000, Age and ageing.

[50]  Panos Deloukas,et al.  The largest prospective warfarin-treated cohort supports genetic forecasting. , 2009, Blood.

[51]  Thomas M. Ludden,et al.  Evaluation of a Bayesian Regression Program for Predicting Warfarin Response , 1989, Therapeutic drug monitoring.

[52]  D. Witt,et al.  Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. , 2005, Chest.

[53]  M. Rieder,et al.  Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.

[54]  M. Moia,et al.  Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). , 2001, Haematologica.

[55]  R L Berg,et al.  Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing , 2010, Clinical pharmacology and therapeutics.

[56]  M. Leaning,et al.  Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy. , 1999, British journal of clinical pharmacology.

[57]  Janice D Nunnelee,et al.  Review of an Article: The international Warfarin Pharmacogenetics Consortium (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. NEJM 360 (8): 753-64. , 2009, Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing.